← Search & browse all drugs
VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Drugs for treatment of hyperkalemia and hyperphosphatemia
patiromer calcium
V03AE09
Forms & Strengths
- Oral powder for suspension: 8.4 g
- Oral powder for suspension: 16.8 g
- Oral powder for suspension: 25.2 g
Adult Dosing
- Initial dose: 8.4 g orally once daily
- Titrate based on serum potassium levels at intervals of 1 week or more
- Maximum dose: 25.2 g orally once daily
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Treatment of hyperkalemia in adults
Mechanism of Action
- Non-absorbed cation exchange polymer that binds potassium in the lumen of the gastrointestinal tract
- Increases fecal potassium excretion, thereby reducing serum potassium levels
Contraindications
- History of a hypersensitivity to patiromer or any of its components
Adverse Reactions
- Constipation
- Hypomagnesemia
- Diarrhea
- Nausea
- Abdominal discomfort
- Flatulence
Drug Interactions
- Binds to and decreases the absorption of numerous concomitantly administered oral medications
- Separate administration of other oral medications by at least 3 hours before or 3 hours after patiromer
Curated Content: Needs Vetting Before Put to Clinical Use